While it’s unclear at this stage precisely which retinal disease indication PYC will target in its clinical program, it’s interesting to compare today’s results in a retinal organoid with those of ProQR’s QR-421a for the treatment of retinitis pigmentosa due to USH2A exon 13 mutations.
Development of QR-421a is currently at Phase 1/2 stage with results expected next year. In Pro QR’s published pre-clinical study results, a single intravitreal injection in a retinal organoid or optic cup model at a dose of 5µm achieved somewhat less than 50% exon-skipping.
PYC’s result of 91% exon-skipping after a single 5µm dose looks very promising.
https://www.proqr.com/wp-content/up...ment-of-RP-due-to-USH2A-exon-13-mutations.pdf
https://www.proqr.com/wp-content/uploads/2019/05/ProQR_QR-421a_ARVO-2019_Presentation.pdf
- Forums
- ASX - By Stock
- PYC
- Ann: Successful Major Milestone - Human Retina in a Dish Models
Ann: Successful Major Milestone - Human Retina in a Dish Models, page-5
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
13.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $606.5M |
Open | High | Low | Value | Volume |
13.0¢ | 13.5¢ | 13.0¢ | $58.25K | 445.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 498267 | 12.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 98858 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 498267 | 0.125 |
22 | 1475209 | 0.120 |
17 | 1433382 | 0.115 |
17 | 693687 | 0.110 |
15 | 1393373 | 0.105 |
Price($) | Vol. | No. |
---|---|---|
0.130 | 23858 | 3 |
0.135 | 1704237 | 14 |
0.140 | 962341 | 7 |
0.145 | 561393 | 5 |
0.150 | 875000 | 6 |
Last trade - 13.11pm 15/07/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |